<SEC-DOCUMENT>0001193125-24-247665.txt : 20241030
<SEC-HEADER>0001193125-24-247665.hdr.sgml : 20241030
<ACCEPTANCE-DATETIME>20241030171903
ACCESSION NUMBER:		0001193125-24-247665
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20241030
DATE AS OF CHANGE:		20241030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CalciMedica, Inc.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273949
		FILM NUMBER:		241411512

	BUSINESS ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-952-5500

	MAIL ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CalciMedica, Inc. /DE/
		DATE OF NAME CHANGE:	20230322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG VISION, INC.
		DATE OF NAME CHANGE:	20170717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d873881d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-273949 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff0200"><B>The information in this preliminary prospectus supplement is not
complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer
to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff0200"><B>SUBJECT TO COMPLETION, DATED OCTOBER&nbsp;30, 2024 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus Dated
August&nbsp;18, 2023) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g873881g01k01.jpg" ALT="LOGO" STYLE="width:3.41553in;height:0.689497in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195; Shares of Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering&#8195;&#8195;&#8195;&#8195;shares of our common stock at a purchase price of $&#8195;per share.&nbsp;Our common stock is listed on The Nasdaq
Capital Market under the symbol &#147;CALC.&#148; The last reported sale price of our common stock on The Nasdaq Capital Market on October&nbsp;29, 2024 was $3.93 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, the aggregate market value of our outstanding shares of common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> was $36,300,351.90, based on 10,750,156 outstanding shares of common stock, of which 6,849,123 shares were held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> and a price of $5.30
per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on September&nbsp;6, 2024 (a date within 60 days of the date hereof). As of the date of this prospectus supplement, we have sold $256,961.87 of
securities pursuant to General Instruction I.B.6. of Form <FONT STYLE="white-space:nowrap">S-3</FONT> during the prior <FONT STYLE="white-space:nowrap">12-month</FONT> calendar period that ends on, and includes, the date of this prospectus (but
excluding this offering). In no event will we sell securities pursuant to such registration statement in a public primary offering with value exceeding more than <FONT STYLE="white-space:nowrap">one-third</FONT> of our public float in any <FONT
STYLE="white-space:nowrap">12-month</FONT> calendar period so long as our public float remains below $75.0&nbsp;million and General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> continues to apply to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under applicable Securities and Exchange Commission rules and are
subject to reduced public company reporting requirements. See the section titled &#147;Prospectus Supplement Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#147;<A HREF="#supptoc873881_4">Risk
 Factors</A>&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-11</FONT> of this prospectus supplement, page 7 of the accompanying prospectus and under similar headings in the documents incorporated by reference into this prospectus
supplement and the accompanying prospectus. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2.5pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2.5pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2.5pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to CalciMedica, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:2.5pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We have agreed to reimburse the underwriter for certain expenses. See &#147;Underwriting.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the shares offering pursuant to this prospectus supplement is expected to be made against payment on &#8195;&#8195;&#8195;, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriter an option to purchase up to an additional &#8195;&#8195;&#8195;&#8195; shares of common stock from us at the price to the
public, less the underwriting discount, within 30&nbsp;days of the date of this prospectus supplement. If the underwriter exercises its option in full, the total underwriting discount payable by us will be $&#8195;&#8195;and the total proceeds,
before expenses, to us will be&nbsp;$&#8195;&#8195;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g873881g02k02.jpg" ALT="LOGO" STYLE="width:0.958115in;height:0.319372in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus supplement dated &#8195;&#8195;&#8195;, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc873881_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACCOMPANYING PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_1">ABOUT THIS PROSPECTUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_2">SUMMARY </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_3">RISK FACTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_5">USE OF PROCEEDS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_6">DESCRIPTION OF CAPITAL STOCK </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_7">DESCRIPTION OF DEBT SECURITIES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_8">DESCRIPTION OF WARRANTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_9">LEGAL OWNERSHIP OF SECURITIES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_10">PLAN OF DISTRIBUTION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_11">LEGAL MATTERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_12">EXPERTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_13">WHERE YOU CAN FIND MORE INFORMATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of a &#147;shelf&#148; registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;), on August&nbsp;11, 2023, which was declared effective by the SEC on August&nbsp;18, 2023. This document is in two parts. Effective as of the filing of this prospectus supplement, no additional shares of our
common stock will be offered or sold pursuant to the $17,068,386 at the market offering agreement prospectus filed with the SEC on August&nbsp;11, 2023, as amended by the prospectus supplement filed with the SEC on March&nbsp;29, 2024 (the &#147;at
the market offering agreement prospectus&#148;). A total of $332,223.63 of shares of common stock have been sold pursuant to the at the market offering agreement prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first part is this prospectus supplement, which describes the specific terms of this common stock offering and adds to and updates information contained
in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this
prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document
incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in
another document having a later date &#150; for example, a document incorporated by reference in the accompanying prospectus &#150; the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the
current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the underwriter has not, authorized anyone to provide any information other than that contained or
incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriter take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities
offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information contained in
this prospectus supplement or the accompanying prospectus, or incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or of any sale of our common stock. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and
therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain
Information by Reference&#148; in this prospectus supplement and in the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the underwriter are offering to sell, and seeking
offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be
restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such
person to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, all references in this prospectus supplement and the accompanying prospectus to
&#147;CalciMedica,&#148; &#147;we,&#148; &#147;us,&#148; &#147;the Company&#148; and &#147;our,&#148; and similar designations, except where the context requires otherwise, refer collectively to CalciMedica, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein,
including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;would,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein
include, among other things, statements about: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the success, cost and timing of our development activities, <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the timing and outcome of our current and future clinical trials, and the reporting of
data from those trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of our technologies and our ability to execute on our corporate strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific, medical, commercial and management personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our working capital needs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength and breadth of our patent portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the therapeutic potential of Auxora and our other product candidates and the expected patient populations, market
opportunities, commercial potential and commercialization strategy thereof; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our cash runway and expected use of cash, cash equivalents and short-term investments;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to obtain additional funding and the ability to obtain such funding for our operations, including
funding necessary to develop and commercialize our product candidates, subject to regulatory approvals: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and plans to contract with third-party suppliers and manufacturers and their ability to perform
adequately; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected competitive position; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain our corporate infrastructure, including our ability to design and maintain an
effective system of internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legislative and regulatory developments in the United States and other foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential claims relating to our intellectual property or other legal proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding future economic conditions or our financial performance; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and adequately protect intellectual property rights for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval for our product candidates and any related restrictions, limitations
and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to extend our operating capital; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to satisfy the Nasdaq listing requirements and have our stock continue to trade on
Nasdaq; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">statements of belief and any statement of assumptions underlying any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in
this prospectus supplement, particularly in the section titled &#147;Risk Factors,&#148; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do
not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this
prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. We do not
assume any obligation to update any forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents we
incorporate by reference. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully, especially the
risks of investing in our common stock discussed in the section titled &#147;Risk Factors&#148; and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as
amended, and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2024, both of which are incorporated by reference in this prospectus supplement, along with our consolidated financial statements
and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company Overview </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon calcium release-activated calcium
(&#147;CRAC&#148;) channels and would constitute a new class of drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a company focused on the discovery and development of CRAC channel
inhibitors. Clinical and preclinical data have demonstrated that the inhibition of CRAC channels may have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities. Our work has shown
compelling evidence of the involvement of CRAC channels in a broad spectrum of both acute critical illnesses and chronic diseases that have the common thread of inflammation or immunologic activity in their pathogenesis. We intend to leverage our
CRAC channel inhibitor platform to develop therapeutics for indications where this dual mechanism of action has the potential for clinical benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or
endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. Multiple Phase 2 clinical trials with Auxora have been conducted: an open-label trial in acute pancreatitis (&#147;AP&#148;), a placebo-controlled
double-blinded trial in AP (which we refer to as &#147;CARPO&#148;), an investigator led open label trial in asparaginase pancreatic toxicity (&#147;AIPT&#148;) (which we also refer to as &#147;CRSPA&#148;) in which the first cohort of patients has
been completed, a placebo-controlled double-blind trial in severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> pneumonia (which we also refer to as &#147;CARDEA&#148;) and an investigator led open-label trial in
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pneumonia patients with acute respiratory distress syndrome (&#147;ARDS&#148;). We observed in all of these trials that patients treated with Auxora experienced a reduced time to recovery and a
reduction of organ damage. We believe the consistency of the results we observed from these trials in two different acute critical care conditions are mutually supportive and reinforce our plans to further pursue the use of Auxora in several
additional acute critical illnesses including acute kidney injury (&#147;AKI&#148;) where we are currently running a Phase 2 trial (which we also refer to as &#147;KOURAGE&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Developments </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2024,
the Company announced late-breaking positive data from CARPO, the Company&#146;s international, randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial evaluating Auxora for the treatment of AP with accompanying SIRS. These data
demonstrate the potential of Auxora to address the significant disease burden of AP for the estimated 300,000 U.S. patients hospitalized for AP annually, with an estimated 100,000 with accompanying SIRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2b CARPO trial intended to establish Auxora&#146;s dose-response and efficacy in AP with accompanying SIRS. The trial reached its target enrollment
of 216. Patients were randomized into four groups to receive either </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
high 2.0 mg/kg dose (n=53), medium 1.0 mg/kg dose (n=56) or low 0.5 mg/kg dose (n=52) of Auxora or a matched dose of placebo (n=53) intravenously every 24 hours for a total of three doses.
Treatment and observation of patients continued for 30 days. CT scans to evaluate pancreatic inflammation and necrosis were performed at study entry and at 30 days. Patients were stratified by baseline hematocrit, a biomarker for inflammation
severity and were well-matched for all baseline characteristics with the exception that the placebo group had approximately 12% lower proportion of hyper-inflamed patients than the study overall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Efficacy&nbsp;&amp; Safety Data </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition
to the topline data previously reported in June 2024, the Phase 2b CARPO trial met its study objective by showing clinically meaningful reductions for observed high and/or medium dose Auxora patients compared to placebo or combined placebo and low
dose Auxora patients in additional key endpoints including statistically significant reductions in rates of <FONT STYLE="white-space:nowrap">new-onset</FONT> severe respiratory failure and <FONT STYLE="white-space:nowrap">new-onset</FONT> persistent
respiratory failure, reductions in <FONT STYLE="white-space:nowrap">new-onset</FONT> necrotizing pancreatitis, reduced times to medically indicated discharge and reductions in the proportion of patients requiring long hospital stays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New onset severe respiratory failure, defined as (i)&nbsp;receiving invasive mechanical ventilation or (ii)&nbsp;use of either high-flow nasal cannula or <FONT
STYLE="white-space:nowrap">non-invasive</FONT> mechanical ventilation for 48 hours or longer, occurred in 0% of high dose patients, 0% of medium dose patients, 8.3% of low dose patients, and 8.5% of placebo patients, representing a 100% (p = 0.0027)
relative risk reduction when combined high and medium dose patients were compared to combined low dose and placebo patients. <FONT STYLE="white-space:nowrap">New-onset</FONT> persistent respiratory failure, defined as (i)&nbsp;severe respiratory
failure or (ii)&nbsp;not severe respiratory failure but PaO<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> /FiO<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> of 300 or lower for 48 hours or longer and use of <FONT
STYLE="white-space:nowrap">low-flow</FONT> oxygen support, occurred in 8% of high dose patients, 1.9% of medium dose patients, 10.4% of low dose patients, and 17% of placebo patients, representing a 64.2% (p = 0.0476) relative risk reduction when
combined high and medium dose patients were compared to combined low dose and placebo patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, new onset necrotizing pancreatitis,
measured on day 30 occurred in 29.7% of high dose patients, 40.8% of medium dose patients, 38.6% of low dose patients, and 37.0% of placebo patients, representing a relative risk reduction of approximately 20% for high dose patients compared to
placebo patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Median time to medically indicated discharge, defined as (i)&nbsp;no clinical evidence of infection necessitating continued
hospitalization, (ii)&nbsp;solid food tolerance, and (iii)&nbsp;abdominal pain resolved or controlled with <FONT STYLE="white-space:nowrap">non-opiate</FONT> medications, was 89.0 hours for high dose patients, 104.5 hours for medium dose patients,
109.5 hours for low dose patients, and 104.0 hours for placebo patients, demonstrating a reduction of 15.0 hours for high dose patients when compared to placebo. Long hospital stays were reduced in combined high and medium dose patients compared to
combined low dose and placebo patients, with 18% vs 31% of patients in the hospital longer than 7 days, 5% vs 10% longer than 14 days, and 1% vs 6% longer than 21 days, respectively. There were no high dose patients who stayed in the hospital longer
than 21 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When key <FONT STYLE="white-space:nowrap">endpoints&#151;all-cause</FONT> mortality, <FONT STYLE="white-space:nowrap">new-onset</FONT>
severe respiratory failure, <FONT STYLE="white-space:nowrap">new-onset</FONT> necrotizing pancreatitis, and time to medically indicated discharge&#151;were integrated into a win ratio analysis, the high dose of Auxora outperformed placebo by a
similar margin across all endpoints and delivered a stratified win ratio of 1.640 (p = 0.0372). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in prior Phase 2 trials, Auxora provided patients with
clinically meaningful improvement and was well-tolerated. There was a trend of decreasing treatment emergent serious adverse event (&#147;TESAE&#148;) rates with increasing doses of drug. Additionally, there were no drug-related TESAEs or deaths in
patients receiving the high dose of Auxora. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Planned Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Planning for a Phase 3 program of Auxora in patients with AP with accompanying SIRS is ongoing, with the CARPO trial results expected to inform the design and
characteristics, pending an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting with the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Update </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our financial statements for
the quarter ended September&nbsp;30, 2024 will not be available until after this offering is completed and consequently will not be available to you prior to investing in our common stock in this offering. Based upon preliminary estimates and
information available to us as of the date of this prospectus supplement, we had approximately $14.6&nbsp;million of cash, cash equivalents and short-term investments as of September&nbsp;30, 2024. We have not yet completed <FONT
STYLE="white-space:nowrap">our&nbsp;quarter-end&nbsp;financial</FONT> close process for the quarter ended September&nbsp;30, 2024. This estimate of our cash, cash equivalents and short-term investments as of September&nbsp;30, 2024 is preliminary,
unaudited and is subject to change upon completion of our financial statement closing procedures. The review of our financial statements for the three and nine months ended September&nbsp;30, 2024 is ongoing and could result in changes to these
amounts. Additional information and disclosure would be required for a more complete understanding of our financial position and results of operations as of September&nbsp;30, 2024. Our independent registered public accounting firm has not audited,
reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Information </I></B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in
Delaware in February 2015, upon conversion of Graybug, LLC, which was organized in May 2011. Our principal executive offices are located at 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037, and our telephone number is <FONT
STYLE="white-space:nowrap">(858)&nbsp;952-5500.&nbsp;Our</FONT> corporate website address is www.calcimedica.com. Information contained on or accessible through our website is not a part of this prospectus supplement, the accompanying prospectus or
any related free writing prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus
supplement, the accompanying prospectus and the information incorporated herein and therein by reference contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred
to in this prospectus, including logos, artwork and other visual displays, may appear without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;or TM symbols, but such references are not intended to indicate, in any way, that
their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or
sponsorship of us by, any other companies. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </I></B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). For as long as we
continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&nbsp;not being required to comply
with the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, (2)&nbsp;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and
(3)&nbsp;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an emerging growth company, we
are only required to provide two years of audited financial statements and two years of selected financial data in our periodic reports. We may take advantage of these exemptions until December&nbsp;31, 2025 or
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until we are no longer an &#147;emerging growth company,&#148; whichever is earlier. We will cease to be an emerging growth company prior to the end of such period if certain earlier events
occur, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), our annual gross revenues
exceed $1.235&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private
companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date
that we are no longer an emerging growth company, or we affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), upon issuance of a new or
revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies and the date on which we will adopt the recently issued accounting standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal
year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="46%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by CalciMedica in this offering </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195; shares (or&#8195;&#8195;&#8195;&#8195;shares if the underwriter exercises its&nbsp;over-allotment&nbsp;option in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="46%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be immediately outstanding after this offering </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195; shares (or&#8195;&#8195;&#8195;&#8195;shares if the underwriter exercises its&nbsp;over-allotment&nbsp;option in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="46%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from this offering will be approximately $&#8195;&#8195;million (or $&#8195;&#8195;million if the underwriter exercises its&nbsp;over-allotment&nbsp;option in full), after deducting the underwriting discounts
and commissions and estimated offering expenses payable by us. We plan to use the net proceeds from this offering primarily to fund the advancement of our clinical programs and for working capital and general corporate purposes. See the section
titled &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="46%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves significant risks. See the section titled &#147;Risk Factors&#148;, and the information under similar headings in other documents incorporated by reference into this prospectus supplement for a discussion
of factors to consider carefully before deciding to invest in shares of common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="46%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market symbol </P></TD>
<TD>&#147;CALC&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 10,750,156 shares of our
common stock outstanding as of June&nbsp;30, 2024, and excludes the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">286,437 shares of common stock issuable upon the exercise of outstanding common stock warrants at a weighted
average exercise price of $25.53 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,140,954 shares of common stock issuable upon the exercise of outstanding stock options at a weighted-average
exercise price of $5.95 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">55,060 additional shares of common stock reserved for future issuance under our equity incentive plan;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">122,545 additional shares of common stock reserved for future issuance under our employee stock purchase plan;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">306,506 shares of common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> common stock warrants at an exercise price of $0.0001 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">75,747 shares of common stock issuable upon the exercise of outstanding placement agent common stock warrants at
an exercise price of $0.0001 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,683,931 shares of common stock issuable upon the exercise of outstanding Tranche A common stock warrants at an
exercise price of $5.36 per share (which expired on July&nbsp;27, 2024); and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,683,931 shares of common stock issuable upon the exercise of outstanding Tranche B common stock warrants at an
exercise price of $7.15 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the
outstanding common stock warrants, options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> common stock warrants, Tranche A common stock warrants (which expired on July&nbsp;27, 2024) and Tranche B common stock warrants described above. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and
uncertainties described below together with all other information contained in this prospectus supplement, the accompanying prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus supplement and the
accompanying prospectus. If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose
all or part of your investment. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price of our common stock in this offering is higher than the net tangible book value per share of our common stock. Therefore, if you purchase
shares of our common stock in this offering, you will pay a price per share that exceeds our net tangible book value per share after this offering. To the extent outstanding options or warrants are exercised, you will incur further dilution. Based
on the offering price of $&#8195;&#8195;per share, our as adjusted net tangible book value as of June&nbsp;30, 2024 would have been $&#8195;&#8195;million, or $&#8195;&#8195;per share, representing an immediate decrease in the net tangible book
value per share of $&#8195;&#8195;to existing stockholders and an immediate dilution of $&#8195;&#8195;in net tangible book value per share to new investors purchasing common stock in this offering, representing the difference between our as
adjusted net tangible book value per share after giving effect to this offering and the offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion over the use of
our cash and cash equivalents, including the net proceeds we receive in this offering, and despite our efforts may not use them in a manner that increases the value of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents, including the net proceeds we receive in this offering, to fund our operations and
could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect
on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that
loses value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will need substantial additional funding to meet our financial obligations and to pursue our
business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require substantial future capital in order to complete planned and future clinical and preclinical development for our product candidates and
potential commercialization of these product candidates, if any are approved. We expect our spending levels to significantly increase in connection with our planned clinical trials of Auxora. In addition, if we obtain marketing approval for any of
our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our
continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our clinical trials, our research and development programs or other operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in the
near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a
substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Upon completion of this
offering, we will have&#8195;&#8195;&#8195;&#8195;shares of common stock outstanding. These shares may be resold into the public market immediately without restriction, unless owned or purchased by our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, shares subject to outstanding options or that are otherwise issuable under our equity compensation plans, all of which shares we have registered
under the Securities Act of 1933, as amended, on a registration statement on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below, to the extent applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $&#8195;&#8195; million, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. We currently intend to use the net proceeds from this offering primarily to fund the advancement of our clinical programs and for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in or
<FONT STYLE="white-space:nowrap">in-license</FONT> of complementary products, technologies or businesses, and we could use a portion of the net proceeds from this offering for such activities. We currently do not have any agreements, arrangements or
commitments with respect to any potential acquisition, investment or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This expected use of our net proceeds from this offering represents our
intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. Predicting the cost necessary to develop and market product candidates can be difficult, therefore, the
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our product candidate development, the status of and results from clinical trials, as well as any collaborations that we
may enter into with third parties for our product candidates, and any unforeseen cash needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, our management will retain broad discretion
over the allocation of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering. The timing and amount of our actual expenditures will be
based on many factors, including cash flows from operations and the anticipated growth of our business. Pending these uses, we expect to invest the net proceeds in short-term, interest bearing obligations, certificates of deposit or direct or
guaranteed obligations of the United States. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are readily available to fund our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the planned use of proceeds described above and current operating plan, we believe that the net proceeds from this offering and our existing cash and
cash equivalents and short-term investments will be sufficient to enable us to fund our operating expenses and capital expenditure requirements&#8195;&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be
incorrect, and we could use our available capital resources sooner than we currently expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the
operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your interest will be immediately diluted to the extent of the difference between the offering price per
share and the as adjusted net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of June&nbsp;30, 2024 was approximately $13.8&nbsp;million, or $1.29 per share of common stock based upon
10,750,156 shares outstanding. Net tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding on June&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering at the offering price of
$&#8195;&#8195; per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2024 would have been $&#8195;&#8195;million, or
$&#8195;&#8195;per share. This represents an immediate increase in net tangible book value per share of $&#8195;&#8195;to existing stockholders and immediate dilution of $&#8195;&#8195;in net tangible book value per share to new investors purchasing
common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the offering price per share paid by new investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this per share dilution to the new investors purchasing shares of our common stock in this offering: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#8201;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;1.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to sale of shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#8201;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#8201;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information above assumes that the underwriter does not exercise the&nbsp;over-allotment&nbsp;option. If the underwriter
exercises the&nbsp;over-allotment&nbsp;option in full, the as adjusted net tangible book value as of June&nbsp;30, 2024 will increase to $&#8195;&#8195;per share, representing an immediate increase in net tangible book value to existing stockholders
of $&#8195;&#8195;per share and an immediate dilution of $&#8195;&#8195;per share to new investors purchasing common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number
of shares of our common stock to be outstanding after this offering is based on 10,750,156 shares of common stock outstanding as of June&nbsp;30, 2024, and excludes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">286,437 shares of common stock issuable upon the exercise of outstanding common stock warrants at a weighted
average exercise price of $25.53 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,140,954 shares of common stock issuable upon the exercise of outstanding stock options at a weighted-average
exercise price of $5.95 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">55,060 additional shares of common stock reserved for future issuance under our equity incentive plan;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">122,545 additional shares of common stock reserved for future issuance under our employee stock purchase plan;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">306,506 shares of common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> common stock warrants at an exercise price of $0.0001 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">75,747 shares of common stock issuable upon the exercise of outstanding placement agent common stock warrants at
an exercise price of $0.0001 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,683,931 shares of common stock issuable upon the exercise of outstanding Tranche A common stock warrants at an
exercise price of $5.36 per share (which expired on July&nbsp;27, 2024); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,683,931 shares of common stock issuable upon the exercise of outstanding Tranche B common stock warrants at an
exercise price of $7.15 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any options are exercised, new options are issued under our
equity incentive plans or we otherwise issue additional shares of common stock in the future at a price less than the offering price, there may be further dilution to new investors purchasing common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an underwriting agreement with JonesTrading Institutional Services LLC (&#147;Jones&#148;), as the underwriter and the book-running manager of
this offering. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus supplement, the underwriter has agreed to purchase, and we have agreed to sell to the underwriter, the respective number of
shares of common stock shown opposite its name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>of&nbsp;Common&nbsp;Stock</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JonesTrading Institutional Services LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="padding-bottom:3pt ;">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the underwriter to purchase the shares of common stock included in
this offering are subject to approval of legal matters by counsel and to other conditions. The underwriting agreement provides that the underwriter will purchase all of the shares of common stock (other than those covered by the option to purchase
additional described below) if any of them are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of common stock sold by the underwriter to the public will initially be offered at the
initial public offering price set forth on the cover of this prospectus supplement. Any shares sold by the underwriter to securities dealers may be sold at a discount from the initial public offering price not to exceed a concession of
$&#8195;&#8195; per share of common stock. If all the shares of common stock are not sold at the initial offering price, the underwriter may change the offering price and the other selling terms. No such reduction will change the amount of proceeds
to be received by us as set forth on the cover of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriter an over-allotment option. This option,
which is exercisable for up to 30 days after the date of this prospectus supplement, permits the underwriter to purchase a maximum of additional shares from us to cover over-allotments. If any shares are purchased with this over-allotment option,
the underwriter will purchase shares in approximately the same proportion as shown in the table above. If the underwriter exercises all or part of this option, they will purchase shares covered by the option at the public offering price that appears
on the cover page of this prospectus supplement, less the underwriting discount. If this option is exercised in full, the total price to the public will be $&#8195;&#8195;and the total proceeds to us will be $&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Discounts and Commissions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us in connection with this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;Per&nbsp;Share&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;Without&#8195;&#8194;</B><br><B>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With</B><br><B>&#8195;&#8195;Option&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Underwriting discount and commissions payable by us</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to company, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our total expenses of the offering, excluding the underwriting discounts and commissions, will be
approximately $&#8195;&#8195;, which includes the fees and expenses for which we have agreed to reimburse the underwriter, including fees and expenses of its counsel, up to a maximum amount of $75,000.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the
underwriter against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriter may be required to make because of any of those liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Ups</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our officers and directors have agreed that, for a period of 60 days from the date of this prospectus supplement, we and they will not, without the
prior written consent of Jones, dispose of or hedge any shares or any securities convertible into or exchangeable for our common stock, subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq
Capital Market under the symbol &#147;CALC&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter may purchase and sell shares in the open market. Purchases and sales in the open market may include
stabilizing purchases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Short sales involve secondary market sales by the underwriter of a greater number of shares than it is required
to purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Covering transactions involve purchases of shares in the open market in order to cover short positions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To close a naked short position, the underwriter must purchase shares in the open market. A naked short position
is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To close a covered short position, the underwriter must purchase shares in the open market.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions involve bids to purchase shares so long as the stabilizing bids do not exceed a
specified maximum. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriter for its
own account, may have the effect of preventing or retarding a decline in the market price of the shares. They may also cause the price of the shares to be higher than the price that would otherwise exist in the open market in the absence of these
transactions. The underwriter may conduct these transactions on The Nasdaq Capital Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. If the underwriter commences any
of these transactions, it may discontinue them at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with this offering, the underwriter may engage in passive market
making transactions in the shares on The Nasdaq Capital Market, prior to the pricing and completion of the offering. Passive market making consists of displaying bids on The Nasdaq Capital Market no higher than the bid prices of independent market
makers and making purchases at prices no higher than those independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are limited to a specified percentage of the passive market maker&#146;s average
daily trading volume in the shares during a specified period and must be discontinued when that limit is reached. Passive market making may cause the price of the shares to be higher than the price that otherwise would exist in the open market in
the absence of those transactions. If the underwriter commences passive market making transactions, it may discontinue them at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic
Offer, Sale and Distribution of Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter or certain of the securities dealers may distribute
prospectuses by electronic means, such as <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriter is a full service financial institution engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, principal investment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hedging, financing and brokerage activities. The underwriter and its affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of its
business for which they may receive customary fees and reimbursement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of its various business activities, the
underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for
its own account and for the accounts of its customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our
affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they
acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales Outside the United States </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of our common stock, or the possession,
circulation or distribution of this prospectus supplement or any other material relating to us or our common stock in any jurisdiction where action for that purpose is required. Accordingly, the shares of common stock may not be offered or sold,
directly or indirectly, and neither this prospectus supplement nor any other offering material or advertisements in connection with our common stock may be distributed or published, in or from any country or jurisdiction, except in compliance with
any applicable rules and regulations of any such country or jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriter may arrange to sell the common stock offered hereby in certain
jurisdictions outside the United&nbsp;States, either directly or through affiliates, where it is permitted to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member State&#148;) an
offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common shares may be made at any time under the following exemptions under the Prospectus
Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant
to Article&nbsp;3 of the Prospectus Directive. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to our
common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an investor to decide to purchase our common
shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended), including by Directive
2010/73/EU, and includes any relevant implementing measure in the Relevant Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This European Economic Area selling restriction is in addition
to any other selling restrictions set out below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United Kingdom, this prospectus is only addressed to and directed as qualified investors who are (i)&nbsp;investment professionals falling within
Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order); or (ii)&nbsp;high net worth entities and other persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to
(d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged with relevant
persons. Any person who is not a relevant person should not act or relay on this prospectus or any of its contents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an invitation to
the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#147;Securities and Futures Ordinance&#148;), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures
Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement,
invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed
or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;)) under
Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as
defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of
the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined
in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#146;s securities pursuant to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by
operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#147;Regulation 32&#148;). Where the
shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be
transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the
SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interests are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is
to be paid for in cash or by exchange of securities or other assets), (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA,
or (6)&nbsp;as specified in Regulation&nbsp;32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended), or
the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or
to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws
and regulations of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional Investors (&#147;QII&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&nbsp;4 of the FIEL) in relation to the
shares of our common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEA).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&nbsp;4 of the FIEA, has not been made in relation to the shares of our common stock. The shares of our common stock may only be transferred to QIIs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&nbsp;4 of the FIEA) in relation to the
shares of our common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT>
of the FIEA). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&nbsp;4 of the FIEA, has not been made in relation to the shares of our common stock. The shares of our common stock may only be transferred
en bloc without subdivision to a single investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult
with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriter is not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection
with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No placement
document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;),
and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated investors&#148; (within the
meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act
so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt
Investors in Australia must not be offered for sale in Australia in the period of 12&nbsp;months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not
be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter&nbsp;6D of the Corporations Act. Any person acquiring shares must observe
such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account
of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether
the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the Company, or the shares have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been
and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israel </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document does not constitute a
prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at,
and any offer of the securities hereunder is directed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only at, (i)&nbsp;a limited number of persons in accordance with the Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Securities Law, consisting
primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS
50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under
the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and
agree to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#147;DFSA&#148;). This
prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any
documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be
illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized
financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock being offered by this prospectus supplement will be passed upon for us by Cooley LLP, San Diego, California. Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York is acting as counsel for the underwriter in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of CalciMedica, Inc. appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2023, as amended by Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K/A,</FONT> have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set
forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the
report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.calcimedica.com. Our website is not a part of this prospectus supplement and is not
incorporated by reference in this prospectus supplement, and the inclusion of our website address in this prospectus supplement is only an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we filed with the SEC. The registration statement contains more information than this
prospectus supplement and the accompanying prospectus regarding us and the securities, including certain exhibits and schedules. You can obtain a copy of the registration statement from the SEC&#146;s internet site. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc873881_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference in this prospectus supplement and the accompanying prospectus much of the information we file with the SEC,
which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying prospectus is considered to be
part of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus supplement and the accompanying prospectus is continually updated and those future filings may
modify or supersede some of the information included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the
statements in this prospectus supplement, the accompanying prospectus or any document previously incorporated by reference have been modified or superseded. This prospectus supplement and the accompanying prospectus incorporate by reference the
documents listed below (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39538)</FONT> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the
portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000095017024038064/calc-20231231.htm">March<U></U>&nbsp;28, 2024</A>, as amended by Amendment No.&nbsp;1 to our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K/A</FONT> for the year ended December&nbsp;31, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524120151/d821804d10ka.htm">April<U></U> 29, 2024</A>;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000095017024058744/calc-20240331.htm">May
 13, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000095017024095490/ck0001534133-20240630.htm">August&nbsp;12, 2024</A>; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337d8k.htm">January
<U></U> 22, 2024</A> (as amended by the Current Report on Form <FONT STYLE="white-space:nowrap">8-K/A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/d738337d8ka.htm">January 24, 2024</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524033981/d777996d8k.htm">February
<U></U> 13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524081584/d818025d8k.htm">March<U></U> 29, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524092036/d690122d8k.htm">April 10,
2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524169805/d124614d8k.htm">June 27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524207754/d884220d8k.htm">August 27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001534133/000119312524247004/d885957d8k.htm">October&nbsp;30,
 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312524247643/d894566d8k.htm">October&nbsp;30, 2024</A> (to the extent the information in such reports is filed and not furnished);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312524179344/d34221ddef14a.htm">Schedule
 14A</A>, filed with the SEC on July 16, 2024 (other than the portions thereof that are furnished and not filed); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312520249563/d99492d8a12b.htm">Form
 8-A</A>, filed with the SEC on September<U></U> 21, 2020, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CalciMedica, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>505
Coast Boulevard South, Suite 307 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>La Jolla, California 92037 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attn: Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">952-5500</FONT> </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g873881g13n04.jpg" ALT="LOGO" STYLE="width:3.38167in;height:0.671196in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">From time to
time, we may offer and sell up to an aggregate amount of $100,000,000 of any combination of the securities described in this prospectus, either individually or in combination, in one or more offerings. We may also offer securities as may be issuable
upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one
or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should
carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the trading symbol &#147;CALC.&#148; On August&nbsp;9, 2023, the last reported
sale price of our common stock was $3.44 per share. As of August 9, 2023, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately
$17.0 million, based upon 2,912,030 shares of our outstanding common stock held by non-affiliates at the per share price of $5.84, the closing sale price of our common stock on the Nasdaq Capital Market on June 14, 2023. Pursuant to General
Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in no event will we sell securities registered on the registration statement of which this prospectus is a part in a public primary offering with a value exceeding more than <FONT
STYLE="white-space:nowrap">one-third</FONT> of our public float in any <FONT STYLE="white-space:nowrap">12-month</FONT> period so long as our public float remains below $75.0&nbsp;million. As of the date hereof, we have not offered any securities
pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> during the 12 calendar months prior to and including the date of this prospectus. The applicable prospect us supplement will contain information, where
applicable, as to other listings, if any, on the Nasdaq Capital Market or other securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11.5pt; font-family:Times New Roman"><B>Investing
in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#txa873881_3">Risk Factors</A>&#148; on page 7 of this prospectus and any similar section contained
in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers,
on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#147;Plan of Distribution&#148; in this prospectus. If any agents or underwriters are involved in the sale of any securities
with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of
such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August 18, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txa873881_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;), using a &#147;shelf&#148; registration process. Under this shelf registration process, we may, from time to time, offer and sell, either individually or in combination, in one or more offerings, up to a
total dollar amount of $100,000,000 of any combination of the securities described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with
a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also
add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully this prospectus, any applicable prospectus supplement and any
free writing prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148;
before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is
accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this
prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different
or additional information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, the accompanying prospectus supplement or in any related free writing prospectus that we may authorize
to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as
of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable
prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information.
Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on
various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the section titled &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.
Unless the context requires otherwise, references in this prospectus to &#147;CalciMedica,&#148; &#147;we,&#148; &#147;us,&#148; &#147;the Company&#148; and &#147;our&#148; refer to CalciMedica, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon calcium released-activated calcium
(&#147;CRAC&#148;) channels and would constitute a new class of drugs. We are a company focused on the discovery and development of CRAC channel inhibitors. Clinical and preclinical data have demonstrated that the inhibition of CRAC channels may
have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities. Our work has shown compelling evidence of the involvement of CRAC channels in a broad spectrum of both acute critical
illnesses and chronic diseases that have the common thread of inflammation or immunologic activity in their pathogenesis. We intend to leverage our CRAC channel inhibitor platform to develop therapeutics for indications where this dual mechanism of
action has the potential for clinical benefit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2023, the Company (f/k/a Graybug Vision, Inc.) completed its previously announced merger transaction in accordance with the
terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November&nbsp;21, 2022, as amended on February&nbsp;10, 2023 (the &#147;Merger Agreement&#148;), by and among Graybug Vision, Inc. (&#147;Graybug&#148;), Camaro
Merger Sub, Inc., a wholly owned subsidiary of Graybug (&#147;Merger Sub&#148;), and CalciMedica, Inc. (&#147;CalciMedica&#148;), pursuant to which Merger Sub merged with and into CalciMedica, with CalciMedica surviving the merger as a wholly owned
subsidiary of Graybug (the &#147;Merger&#148;). Following the consummation of the Merger, the business previously conducted by CalciMedica became the business conducted by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, each outstanding share of CalciMedica capital stock (after giving effect to the automatic conversion of
all shares of CalciMedica preferred stock into shares of CalciMedica common stock (&#147;preferred stock conversion&#148;), the automatic exercise of certain CalciMedica warrants to purchase shares of CalciMedica capital stock in accordance with
their terms (the &#147;CalciMedica warrant exercises&#148;), the conversion of CalciMedica convertible promissory notes, as may be amended, into CalciMedica common stock pursuant to their terms (&#147;convertible promissory note conversion&#148;)
and the closing of the private placement (as defined below), and excluding any shares held as treasury stock by CalciMedica or held or owned by Graybug or any subsidiary of Graybug or CalciMedica and any dissenting shares) was converted into the
right to receive 0.0288 shares of Graybug common stock, which resulted in the issuance by Graybug of an aggregate of 3,946,540 shares of Graybug common stock to the stockholders of CalciMedica in a transaction exempt from registration under the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;), in reliance on Section&nbsp;4(a)(2) of the Securities Act and the rules promulgated thereunder. In addition, Graybug assumed the CalciMedica 2006 Stock Plan and each outstanding
and unexercised option to purchase CalciMedica common stock and each outstanding and unexercised warrant to purchase CalciMedica capital stock (excluding the warrants which were automatically exercised pursuant to the CalciMedica warrant exercises)
which became options and warrants to purchase shares of Graybug common stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger was treated as a reverse recapitalization under U.S. generally accepted
accounting principles. CalciMedica is considered the accounting acquirer for financial reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the
consummation of the Merger, CalciMedica completed a private placement financing pursuant to which certain investors purchased approximately 596,363&nbsp;shares of CalciMedica common stock for an aggregate purchase price of $10.3&nbsp;million (the
&#147;private placement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the consummation of the Merger, CalciMedica filed a Certificate of Amendment to its
Amended and Restated Certificate of Incorporation changing its name from &#147;CalciMedica, Inc.&#148; to &#147;CalciMedica Subsidiary, Inc.&#148; and Graybug filed a Certificate of Amendment to the Graybug Charter changing its name from
&#147;Graybug Vision, Inc.&#148; to &#147;CalciMedica, Inc.&#148; The Company&#146;s common stock commenced trading on the Nasdaq Capital Market under the ticker symbol &#147;CALC&#148; on March&nbsp;21, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). For as
long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1) not being required to
comply with the independent auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, (2) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)
exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an emerging growth company, we are only
required to provide two years of audited financial statements and two years of selected financial data in our periodic reports. We may take advantage of these exemptions until December 31, 2025 or until we are no longer an &#147;emerging growth
company,&#148; whichever is earlier. We will cease to be an emerging growth company prior to the end of such period if certain earlier events occur, including if we become a &#147;large accelerated filer&#148; as defined in Rule 12b-2 under the
Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;), our annual gross revenues exceed $1.235&nbsp;billion or we issue more than $1.0 billion of non-convertible debt in any three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to
private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until
the date that we are no longer an emerging growth company, or we affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act, upon issuance of a new or revised accounting standard that applies to
our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued
accounting standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller
reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long
as our voting and non-voting common stock held by non-affiliates is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently
completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in February 2015, upon conversion of Graybug, LLC, which was organized in May 2011. Our principal executive
offices are located at 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037, and our telephone number is (858) <FONT STYLE="white-space:nowrap">952-5500.</FONT> Our corporate website address is www.calcimedica.com. Information contained on or
accessible through our website is not a part of this prospectus, the accompanying prospectus or any related free writing prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and
trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate, in any
way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such
securities, either individually or in combination, up to a total dollar amount of $100,000,000, from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on
terms to be determined by market conditions at the time of any offering. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable
antidilution provisions. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the
specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity date, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exercise, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material or special U.S. federal income tax considerations, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this
prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors or to or through agents, underwriters or
dealers. We and our agents or underwriters reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus
supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those agents or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock.</I></B><B> </B>We may issue shares of our common stock from time to time. The holders of our common stock are entitled to
one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such
dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities
and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions
applicable to our common stock. In this prospectus, we have summarized certain general features of the common stock under &#147;Description of Capital Stock&#151;Common Stock.&#148; We urge you, however, to read the applicable prospectus supplement
(and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock.</I></B><I> </I>We may issue shares of our preferred stock from time to time, in one or more series. Our board of
directors will determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of
redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other
securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred
stock under this prospectus, we will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the
certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of
designation that contains the terms of the series of preferred stock we are offering. In this prospectus, we have summarized certain general features of the preferred stock under &#147;Description of Capital Stock&#151;Preferred Stock.&#148; We urge
you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of
designation that contains the terms of the applicable series of preferred stock. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities.</I></B><I> </I>We may issue debt
securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated
debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or
exchangeable for our common stock or other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any debt securities issued under this prospectus will be issued under one or more documents
called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under &#147;Description of Debt
Securities.&#148; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete
indentures that contain the terms of the debt securities. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the
terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants. </I></B>We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series.
We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities. In this prospectus, we have summarized certain general features of the warrants under &#147;Description of Warrants.&#148; We urge you,
however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as any warrant agreements and warrant
certificates that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this
prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.<I> </I> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in
any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any,
for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. See &#147;Use of Proceeds&#148; in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on the Nasdaq Capital Market under the symbol &#147;CALC.&#148; The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Capital Market or other securities exchange
of the securities covered by the applicable prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed under the section titled &#147;Risk Factors&#148; contained in
our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with
the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in
connection with this offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors
that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of
these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.
Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may
include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost and timing of our development activities, <FONT STYLE="white-space:nowrap">non-clinical</FONT>
studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and outcome of our current and future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of our technologies and our ability to execute on our corporate strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific, medical, commercial and management personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our working capital needs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength and breadth of our patent portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the therapeutic potential of Auxora and our other product candidates, including Auxora&#146;s potential for
increased safety and efficacy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain funding for our operations, including funding necessary to develop and commercialize our
product candidates, subject to regulatory approvals: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to manufacture and conduct preclinical studies and clinical trials of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain our corporate infrastructure, including our ability to design and maintain an
effective system of internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential claims relating to our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and adequately protect intellectual property rights for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval for our product candidates and any related restrictions, ;imitations
and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to extend our operating capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to satisfy the Nasdaq listing requirements and list our shares of common stock on Nasdaq; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the ongoing conflict
between the Ukraine and Russia and the recent and potential future bank failures or other geopolitical events. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these
forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement, in any free writing prospectuses we may authorize for use in connection with a
specific offering, and in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in
subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable
statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and
any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with
a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital
expenditures and working capital. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we
have no current plans, commitments or agreements with respect to any acquisitions. Pending these uses, we intend to invest the net proceeds of any offering under this prospectus in short- and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We will retain broad discretion in determining how we will allocate the net proceeds from the sale of securities under this prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0001 per share,
and 10,000,000 shares of preferred stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of
our capital stock and certain provisions of our restated certificate of incorporation and restated bylaws. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should
refer to our restated certificate of incorporation and restated bylaws, which are incorporated by reference as an exhibit to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of which this Exhibit 4.3 is a part, and to the
provisions of applicable Delaware law. For information on how to obtain copies of our amended and restated certificate of incorporation, amended and restated bylaws and such agreements, which are exhibits to the registration statement of which this
prospectus is a part, see the section titled &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and
then only at the times and in the amounts that our board of directors may determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate
of incorporation established a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for
the remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Preemptive or Similar Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Right to Receive Liquidation Distributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of
and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of preferred stock in
one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or
restrictions, in each case without further vote or action by our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders. Our board of directors is also able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding
and not above the number of shares of that series authorized, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law (the &#147;DGCL&#148;), our amended and restated certificate of incorporation, as
amended, or our restated certificate of incorporation, and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have
the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential
ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Law </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the
provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for
a period of three years following the date on which the person became an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i)&nbsp;shares owned by persons who are directors and also officers and
(ii)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors
of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of
transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested
stockholder status, did own 15% or more of a corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We
also anticipate that Section&nbsp;203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate of Incorporation and Restated Bylaw Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or
prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Board of Directors Vacancies</I>. Our restated certificate of incorporation and restated bylaws authorize only
our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board
of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult
to change the composition of our board of directors but promotes continuity of management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Classified Board</I>. Our restated certificate of incorporation and restated bylaws provide that our board of
directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for
stockholders to replace a majority of the directors on a classified board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders</I>. Our restated certificate of incorporation provides
that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated
bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of
directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a
proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations</I>. Our restated bylaws
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify
certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of
directors or otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Cumulative Voting</I>. The DGCL provides that stockholders are not entitled to the right to cumulate votes
in the election of directors unless a corporation&#146;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Directors Removed Only for Cause</I>. Our restated certificate of incorporation provides that stockholders may
remove directors only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Amendment of Charter Provisions</I>. Any amendment of the above provisions in our restated certificate of
incorporation requires approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Issuance of Undesignated Preferred Stock</I>. Our board of directors has the authority, without further action
by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of
preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Choice of Forum</I>. Our restated certificate of incorporation provides that, to the fullest extent permitted
by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising
pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws provide that the federal district courts of the
United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which we refer to as a Federal Forum Provision. Our decision to
adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts will follow the
holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability
created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the
Exchange Act, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our
stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities
laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the
Federal Forum Provision. These provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and
our directors, officers, and other employees. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Equiniti Trust Company. The transfer agent&#146;s address is 6201 15th Avenue,
Brooklyn, New York 11219. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement related to that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Capital Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the Nasdaq Capital Market under the symbol &#147;CALC&#148;. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq Capital Market or any securities
market or other exchange of the preferred stock covered by such prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the &#147;Trust Indenture Act&#148;). We have filed the form of indenture as an exhibit to
the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us,
the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation,
Merger or Sale;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company (&#147;DTC&#148;), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are
issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of
debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and
Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt
securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing
prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series.
Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will
apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing
prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security
that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements
and forms of warrant certificates containing the terms of the warrants being offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a
part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The
following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular
series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing
prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal
holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below,
indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry
Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means
securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system.
These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in
the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes
along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their
customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not own
securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may be terminated in certain situations as described under &#147;&#151;Special Situations When a Global Security
Will Be Terminated,&#148; or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further
responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval
of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal
holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented
by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global
security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#147;&#151;Special
Situations When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will
be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another
institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed by the account rules of the investor&#146;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the
names of the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated
transactions, block trades or a combination of these methods. A distribution of these securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants. We may sell the
securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule&nbsp;415
under the Securities Act.&nbsp;Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or
trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker other than on the Nasdaq Capital Market or such other securities exchanges or
quotation or trading services. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Such&nbsp;at-the-market&nbsp;offerings,</FONT></FONT> if any, may be
conducted by underwriters acting as principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus
that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options pursuant to which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale.&nbsp;The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement.&nbsp;We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate.&nbsp;Subject to certain conditions, the underwriters will be
obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any option to purchase additional securities.&nbsp;Any public offering price and any discounts or concessions allowed or reallowed or
paid to dealers may change from time to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time.&nbsp;We may use underwriters with whom we have a material relationship.&nbsp;We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time.&nbsp;We will name any agent involved in the offering and
sale of securities, and we will describe any commissions and other compensation we will pay the agent in the prospectus supplement.&nbsp;Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of
its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase
securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future.&nbsp;We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities.&nbsp;Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than common stock, will be new issues of securities with no established trading market.&nbsp;Any agents or
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice.&nbsp;We cannot guarantee the liquidity of the trading markets for any securities. There is
currently no market for any of the offered securities, other than our common stock which is listed on the Nasdaq Capital Market. We have no current plans for listing of the debt securities, preferred stock or warrants on any securities exchange or
quotation system; any such listing with respect to any particular debt securities, preferred stock or warrants will be described in the applicable prospectus supplement or other offering materials, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Rule
103 of Regulation M under the Exchange Act.&nbsp;Overallotment involves sales in excess of the offering size, which create a short position.&nbsp;Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum.&nbsp;Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions.&nbsp;Penalty bids permit the underwriters to reclaim a
selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.&nbsp;Those activities may cause the price of the securities to be higher than it
would otherwise be.&nbsp;If commenced, the underwriters may discontinue any of the activities at any time.&nbsp;These transactions may be effected on any exchange
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">or&nbsp;over-the-counter&nbsp;market</FONT></FONT> or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
agents and underwriters who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market in accordance with Rule&nbsp;103 of Regulation M, during the
business day prior to the pricing of the offering, before the commencement of offers or sales of the securities.&nbsp;Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
makers.&nbsp;In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive
market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced,
may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_12"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst &amp; Young LLP, independent registered public accounting firm, has audited the consolidated financial statements
of CalciMedica, Inc. (formerly Graybug Vision, Inc.) included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022, as amended by Amendment No.1 on Form&nbsp;10-K/A, as set forth in their report, which is incorporated by
reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of CalciMedica, Inc. at December&nbsp;31, 2022 and 2021, and for each of the two years in the period ended
December&nbsp;31, 2022, appearing in CalciMedica, Inc.&#146;s Current Report on Form&nbsp;8-K, dated August&nbsp;11, 2023 have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report
thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the
registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules
filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we
may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer of these securities in any state
where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of
the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC
maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including CalciMedica. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.calcimedica.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txa873881_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-39538.</FONT> The documents incorporated by reference into
this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this document:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2022 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000095017023006795/gray-20221231.htm">March&nbsp;9, 2023</A>, as amended by Form
<FONT STYLE="white-space:nowrap">10-K/A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523090842/d471553d10ka.htm">April&nbsp;4, 2023</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2023 and June&nbsp;30, 2023 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000095017023021775/calc-20230331.htm">May&nbsp;
12, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001534133/000095017023041844/calc-20230630.htm">August&nbsp;11, 2023</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and
<FONT STYLE="white-space:nowrap">8-K/A</FONT> (other than information furnished rather than filed) filed with the SEC on<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523030003/d424959d8k.htm"> February&nbsp;9,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523041092/d461698d8k.htm">February&nbsp;
16, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523059999/d424298d8k.htm">March&nbsp;
3, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523071452/d481564d8k.htm">March&nbsp;
15, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523076714/d485425d8k.htm">March&nbsp;
22, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523090853/d471673d8ka.htm">April&nbsp;
4, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523137097/d474732d8k.htm">May&nbsp;
5, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523143456/d491121d8k.htm">May&nbsp;
12, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523143469/d386273d8ka.htm">May&nbsp;
12, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523144226/d463877d8k.htm">May&nbsp;
15, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523176143/d492533d8k.htm">June&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523209160/d477357d8k.htm">August&nbsp;
10, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1534133/000119312523210794/d441914d8k.htm">August&nbsp;11, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312523166014/d521413d8a12b.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A>&nbsp;filed with the SEC on&nbsp;June 13, 2023, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial filing
of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering of all offerings covered by
this prospectus. These documents include periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> as well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus
is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by
reference into such documents. You should direct any requests for documents by writing us at CalciMedica, Inc., 505 Coast Boulevard South, Suite 307, La Jolla, California 92037, Attn: Corporate Secretary or telephoning us at <FONT
STYLE="white-space:nowrap">(858)&nbsp;952-5500.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by
reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference
into this document modifies or supersedes the statement. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g873881g01k01.jpg" ALT="LOGO" STYLE="width:3.41553in;height:0.689497in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CalciMedica, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:26%;border-bottom:1.00pt solid #000000; width:53%">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;, 2024 </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:26%;border-bottom:1.00pt solid #000000; width:53%">&nbsp;</P> <P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g873881g31k02.jpg" ALT="LOGO" STYLE="width:1.70093in;height:0.570093in;">
 </P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g873881g01k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g873881g01k01.jpg
M_]C_X  02D9)1@ ! 0$ VP#;  #_[16*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R,CDS.3DX' (% $!-:6-R;W-O
M9G0@5V]R9" M($-!3$,@+2!0<F5L:6UI;F%R>2!0<F]S<&5C='5S(%-U<'!L
M96UE;G0@7T]C=&]B #A"24T$)0      $*!3E#Q"A9!9$D.7SO2\3.\X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :V            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ #;     0 ! -L    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@              EP   NP    & &< ,  Q
M &L ,  Q     0                         !              +L
MEP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MEP    !29VAT;&]N9P   NP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )<     4F=H=&QO;F<
M  +L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MXRWU?3?9^D?3ZFS_ *U^C1?K3@8_V.[TNF?;']0(JRG52VS:/TC'[ZVO=O\
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M?0\+H>",+#W%FXV/LL.Y[WNC=8\@-;]%K6>QBH_6OI?4,IN#U'I;1;G]*O\
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MECJWL]KMKMW\XE@NS;>JYO5,G$MI;5C,JQJ2 ;'L]U[@WW;/6=[?9O\ T?\
M-K>21&+4>HT)&?#_ %I?^C(.>XD<(XC$8S/7Y8</#I_=APO_V0 X0DE-!"$
M     %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( -
M  $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    @    ?@$R  (
M   4    G@$[  (    )    LH=I  0    !    O    .@   #;     0
M -L    !061O8F4@4&AO=&]S:&]P(#(U+C$R("A7:6YD;W=S*0 R,#(T.C$P
M.C,P(# W.C$V.C4Y ')R,CDS.3DX     Z !  ,    !__\  * "  0    !
M   "[* #  0    !    EP         & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 4Y%>&EF  !-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   "    !^ 3(  @   !0
M  "> 3L  @    D   "RAVD !     $   "\    Z    -L    !    VP
M  %!9&]B92!0:&]T;W-H;W @,C4N,3(@*%=I;F1O=W,I #(P,C0Z,3 Z,S @
M,#<Z,38Z-3D <G(R.3,Y.3@    #H $  P    '__P  H ( !     $   +L
MH , !     $   "7          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@ SP0! P$B  (1 0,1 ?_$ !P
M 0 !!0$!               ' 0(%!@@$ __$ % 0  $# P($ @8&! H( PD
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M^M;\55M1$[82-)]J:8/LBH'#"<P0%45,A50!$1 $1$ 1$0!$1 %0D!55KNZ
MKS;;*G-LO+75D%%"9*F5L;!C=SL+1]0\5-/VATD39C4U#2 (X2TDY]ZF,)2]
M D+F\5<#E8ZS5W\)6FEK1&Z-M1$V4,=U <,C[UD&=%&M JB(@"(B (B( B(@
M"$XZHJ.QC?H@',$YO#=8^MO%!0N#*JJBB)Z<S@OO25D%7$V2GE9(QPR"TJ=,
M'J"*@V&ZL?(UHRX@!0#Z(K&/:YOJG*NY@@*H@.40!$1 $0E4Y@@*HJ%R^9E8
M'8+AS>&4!]45 <JJ (B( B(@"(B (B( B(@"(B (B( K3OE7=E\W$#N0%'H
MG=,[%8JYWRBH6N]/.T<HR1D+$676%+=;N:.C8][0WF,@QR]>B\_ECO1[*B?7
MMKP;:%4D*T;=5\*BLAIVDS2-9[2O1M+V>2BWX1Z0<JO=>&EN5/4G]#*QXSC8
MKVAV5":?HEQ<?9<BIS!561B$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M^NX<,O! .2,#HMCM/$AKY VLB+&],I7R-4R;>'R*UO1* .!@J->+]>64<%*
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MXX\W$CY%<D6.D-=>:*F!P99&MS[UVU;(/JMOIH,Y]'&UF?8,+<Y.7J)D_1[
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M:T^GR6$]MMOF%'-QI7T-;-3RC!8XM*GG1]&ZDT_30R8SR[_$K1.*EC]'*+A
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MI"2YSY'GON2L];=(W2M=AL(:TC.7.6U\/M'\Q97W!HY@<M:1T4HQ1,8 &M
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MUI/F<GY!:P-QL3RG9;-Q!M4ENO\ 42NYC%4.,@>1L"2<A:UC;V[>Q?-LWO\
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M=/57^1'YJ-HR.RFDJ\+PVRM@KZ1E322MEB> 6N:<KUY\USS6O9@7H51O1"4
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M'!WX*.3P(MN3FNF\]NOS4U<A QLJAI[KQA;./IC9BM,6>&Q62CMM-_-T\;6
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g873881g02k02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g873881g02k02.jpg
M_]C_X  02D9)1@ ! 0$ OP"_  #_[1!\4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R,CDS.3DX' (% $!-:6-R;W-O
M9G0@5V]R9" M($-!3$,@+2!0<F5L:6UI;F%R>2!0<F]S<&5C='5S(%-U<'!L
M96UE;G0@7T]C=&]B #A"24T$)0      $*!3E#Q"A9!9$D.7SO2\3.\X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9^            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ "_     0 ! +\    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@              /0   +<    & &< ,  R
M &L ,  R     0                         !              "W
M/0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M/0    !29VAT;&]N9P   +<    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   #T     4F=H=&QO;F<
M  "W     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M@%TN.UNCG,1\/*KS,2G+K#FUY%;;6!^C@'@/;NC=[M5B?7O_ ,3[_P#CJO\
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M(  R #  ,@ T     0 X0DE-!"(      49-30 J    "  ( 1(  P    $
M 0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M "    !^ 3(  @   !0   "> 3L  @    D   "RAVD !     $   "\
MZ    +\    !    OP    %!9&]B92!0:&]T;W-H;W @,C4N,3(@*%=I;F1O
M=W,I #(P,C0Z,3 Z,S @,#<Z,3DZ,3( <G(R.3,Y.3@    #H $  P    '_
M_P  H ( !     $   "WH , !     $    ]          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M 0   48" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!3D5X:68  $U- "H    (  @!$@ #     0 !   !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    (
M 'X!,@ "    %    )X!.P "    "0   +*':0 $     0   +P   #H
MOP    $   "_     4%D;V)E(%!H;W1O<VAO<" R-2XQ,B H5VEN9&]W<RD
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M%R,F,S4V4I+2)"548H*4PD.$HN+P\?_$ !H! 0$! 0$! 0            4
M! (! P;_Q  L$0 " @(" @$# P,%         0(#!!$%$B$Q$S-!42(R<2,T
MP105)$)A_]H # ,!  (1 Q$ /P"U* 4% 7A&,K(.5@H"](SE8R@H)T41D'*%
M@>1940(0A1 A"%$"$(40(0A1 A"%$"$(40(0A1 A"%$"$(40(0A1 OG-*(HW
M/(T"^BUJ\_V23N7J\O1Y)Z6Q=#?#:<9^\Y_YPC\L5IZ4<^?G!*+8>UP7G:*D
MHJOC\#(3GA(!Y$IQC=/8<<ZO775[?Z4K;5BTM*2853=DVIN.CXC?%:?\'/\
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M(419O5L$M/)(#4,+3C@<UO$>[QEW"BRQ;BMHXG?7!ZD_)V]OKB*#9BLJ"2,
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MRAW\;AIZ NU;MW]@H7LDAH(S*WD\N)*^DN3J2\(XAQMK?ZF?#=-6.J]C*-Q
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g873881g13n04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g873881g13n04.jpg
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MB0FC990QY"5.# LM^KI'1VE\-VW(Z$=S?,]_.9^ZOS%^.._/7IU9YOVCQ+-
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M[,85C"$R=>'$XA+=6R9H+41@;%A6G2:O-&U?O5HF5B#T]_Z>O;C_ .1?<?\
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MOQL=$E0)Y+=D<9<RVDJH2 3! %MC2?PX'(UXF1#);4E33RL^N,;ZXK<>#S5
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1-.--.--.--.--.--.--?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g873881g31k02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g873881g31k02.jpg
M_]C_X  02D9)1@ ! 0$ :P!K  #_[1/44&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R,CDS.3DX' (% $!-:6-R;W-O
M9G0@5V]R9" M($-!3$,@+2!0<F5L:6UI;F%R>2!0<F]S<&5C='5S(%-U<'!L
M96UE;G0@7T]C=&]B #A"24T$)0      $*!3E#Q"A9!9$D.7SO2\3.\X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ !K     0 ! &L    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@              /0   +8    & &< ,P Q
M &L ,  R     0                         !              "V
M/0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M/0    !29VAT;&]N9P   +8    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   #T     4F=H=&QO;F<
M  "V     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M_9Z<;W44N(WNL'MK>YC-VRNKZ?TOIKN2F"O'W?8]'MUPCBX/YSAKJTOU7O\
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M3QWUL^JN3E93NH]-8+7V@?:<>0UQ<T0VZK=M8[<QOZ2M953_ *]-;Z%8SX;
M <T'_P &M;[O^W%Z*.$Y4V/W/;CQ^W7Z'N_,PY/;]R7![E_I^UL\T,?ZQGZH
MOQGML/5B2 [U1ZNTV>IO]=KO;:VH^RO>N>R'_7:_&=@9-67;3;H]IJ:21/T'
M9#6_0_MKT9(IN&[E_-7QGY_WOZG]5=EJH_SM<&O#^[_7_K/-_4_H&3TNJ[)S
M6AF3DPWT@0=C&S#7.;[?4L<[<]=($NR2KYN/W)<?S>&WT;&'@]N/!\JZ222C
M9'__V0 X0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  ,@ P #( -     $ .$))300B      %&34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   @    ?@$R  (    4    G@$[  (    )    LH=I  0    !    O
M .@   !K     0   &L    !061O8F4@4&AO=&]S:&]P(#(U+C$R("A7:6YD
M;W=S*0 R,#(T.C$P.C,P(# W.C,X.C,X ')R,CDS.3DX     Z !  ,    !
M__\  * "  0    !    MJ #  0    !    /0         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
M  $   %& @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 4Y%>&EF  !-30 J    "  ( 1(  P    $  0
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   "
M  !^ 3(  @   !0   "> 3L  @    D   "RAVD !     $   "\    Z
M &L    !    :P    %!9&]B92!0:&]T;W-H;W @,C4N,3(@*%=I;F1O=W,I
M #(P,C0Z,3 Z,S @,#<Z,S@Z,S@ <G(R.3,Y.3@    #H $  P    '__P
MH ( !     $   "VH , !     $    ]          8! P #     0 &   !
M&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $     0
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "K ?X# 2(
M A$! Q$!_\0 '    00# 0                $"!P@#!08$_\0 41   0,"
M! ,"!PH+!08' 0   0 " P01!1(A,08'01-1(C)A<7*QLA05(S0U0G.!DM$6
M)"4S-E)3=)&3P1=BH;/A)D-$5&.B562"@X24TN+_Q  : 0 " P$!
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M&'D@@I6>+KN@ZFF/OK9!-DT.Z'=&8@>%L@!V8)+Z$IH()T2DFXV7EG3%4#-
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MN@ 1E&NB4"P0@ L+6Z(L$(0 60A" !"$( $G1*=EAZV.YV1V R6LAQTLFEP
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M/6%($OBK*Y#W8S3XRU4BM_,TD8Y?39WME<?XVO<NPYG?+H\SO;*X_H%HL/\
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MX7"TE=@--5R9I<^UM'6ZK>)J]1DX^#Q."EY.'JN7V$5+RZ45%SW2_P"B=1\
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M"\L$SSR17-TGN>X_U6?O2M7KJ:/*BF><4K1<MW/E3F0Y3KNO0=DU&]ATI -
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:J2R5"Z<$ U2I E7$=!"$+H A"$ "$(0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
